Liquidia Corporation, also referred to as LQDA, is a late-stage clinical biopharmaceutical company specializing in the innovation and development of various product candidates by using its proprietary technology named PRINT®. This acronym, PRINT, stands for Particle Replication in Non-wetting Templates, visualizing the company's focus on producing precisely engineered nanoparticles to improve the delivery and effectiveness of complex drugs.
Founded in 2004, Liquidia Corp is headquartered in Research Triangle Park, North Carolina. Its primary mission lies in leveraging the unique properties emerging from its ability to design and develop engineered particles. This approach is anticipated to dramatically enhance the safety, function, and performance of numerous therapeutic solutions, specifically in areas that have been limited by traditional technologies.
Liquidia's lead product candidate, called LIQ861, seeks to simplify the management of pulmonary arterial hypertension (PAH). The company expects LIQ861 to improve the therapeutic performance of the compound by using its PRINT technology to produce a dry powder spray formulated exclusively with particles small enough to reach the deep lung’s vasculature. In 2020, this product was under priority review by the U.S. Food and Drug Administration (FDA).
In addition to PAH, Liquidia's PRINT technology has been used to address several other therapeutic areas and paths, ranging from local therapies to systemic diseases. The company has entered numerous collaborations with other industry leaders to grow and empower its robust pipeline.
Liquidia Corp's strength arises from its unique, patented technology platform and the potential it offers to improve drug delivery across a wide variety of diseases. It also benefits from a strong leadership team with extensive industry expertise. Its enduring struggle to deliver better, more reliable medicines has positioned Liquidia Corp as an innovative player in the biopharmaceutical sector. And despite the risks associated with pharmaceutical development, the corporation's high potential in creating transformative therapies using its pioneering technologies has continued to attract keen interest from investors and industry specialists alike.